Deficiency of mitochondrial modulator MCJ promotes chemoresistance in breast cancer.

ABSTRACT: Despite major advances in early detection and prognosis, chemotherapy resistance is a major hurdle in the battle against breast cancer. Identifying predictive markers and understanding the mechanisms are key steps to overcoming chemoresistance. Methylation-controlled J protein (MCJ, also known as DNAJC15) is a negative regulator of mitochondrial respiration and has been associated with chemotherapeutic drug sensitivity in cancer cell lines. Here we show, in a retrospective study of a large cohort of breast cancer patients, that low MCJ expression in breast tumors predicts high risk of relapse in patients treated with chemotherapy; however, MCJ expression does not correlate with response to endocrine therapy. In a prospective study in breast cancer patients undergoing neoadjuvant therapy, l

SUBMITTER: Fernandez-Cabezudo MJ 

PROVIDER: S-EPMC4888911 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature